Navigation Links
Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level
Date:12/1/2008

nd length of lesions, reference vessels, etc - adding additional realism to the equipment selection process.

Mentice - improving patient safety

Mentice is a world leader in medical simulation, providing qualified solutions for training, education and assessment opportunities. With a focus on minimally invasive techniques and procedures, Mentice develops simulation systems for training in a safe environment within the fields of endovascular intervention and endoscopic surgery. The advantages of training with Mentice solutions are well documented enhancing clinical performance, reducing cost, and, in the long term, improving patient safety.

    For further information, please contact
    Goran Malmberg, President/CEO of Mentice.
    Office: +46-31-33-99-401,
    Web:http://www.mentice.com

'/>"/>
SOURCE Mentice AB
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Mentice, Inc. Announces Appointment of Vice-President, Sales and Marketing, Americas
2. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
3. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
4. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
5. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
6. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
7. PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software
8. NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information
9. Brookdale Senior Living Announces Enhanced Web Site
10. T cell immunity enhanced by timing of interleukin-7 therapy
11. The HealthCentral Network and Sister to Sister Form Alliance to Develop Enhanced Online Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Inc. (Nasdaq: NBIX ) today reported that it ... an aggregate of 4,784,689 primary shares of its common ... $2.09 per share, raising aggregate gross proceeds to Neurocrine ... close on or about December 22, 2009, subject to ... statement relating to the shares of common stock to ...
(Date:12/17/2009)... Efficient Mechanism to Pursue Approval in Multiple ... /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... initiated the regulatory approval process for its ... Decentralized Procedure (DCP). The DCP provides an ... simultaneously pursue regulatory approval for a medicinal ...
(Date:12/17/2009)... UNION CITY, Calif., Dec. 17 Abaxis, ... company manufacturing point-of-care blood analysis instruments and rapid ... announced today that it has entered the production ... rapid Avian Influenza Antigen Test. This is a ... antigen in chickens, turkeys and ducks. The disposable, ...
(Date:12/17/2009)... Valerie VanBooven RN BSN author and elder care expert announces the ... Success, Courage and Strength.” Valerie is a contributing author and ... books to be written all year. Now released in paperback, ... office locally. , ... St. Louis, MO (PRWEB) December ...
(Date:12/17/2009)... PricewaterhouseCoopers, Health Research Institute,s Top 10 Health Industry ... control at the head of the list as the ... typically lags trends in the business cycle by a ... new growth for other sectors of the U.S. economy, ... Chin, M.D., partner and leader of PricewaterhouseCoopers, Health Research ...
Breaking Medicine News(10 mins):Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 3Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 4Health News:Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families 2Health News:Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families 3Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 2Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 3Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 4Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 5Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 6Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 7
... May 14 Quark Pharmaceuticals, Inc., a development-stage ... (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., ... "siRNA Therapeutics for Prevention of Ocular and Inner ... Nucleic Acid Diagnostics & Therapeutics. The event was ...
... for Consumers KANSAS CITY, Mo., May 14 ... 8.5 percent,(1) families are living on tighter budgets, and ... Despite these challenges, there are still ways for consumers ... to the National Association of Insurance Commissioners (NAIC). "These ...
... Corporation (Pink Sheets: CGCP) the "Company", a leading developer ... suffering from severe angina, today reported financial results for ... Financial ResultsNet revenues in the first quarter of 2009 ... first quarter net revenues of $2,982,000. During the ...
... New Research on Antioxidant-Enhanced SuncareKENILWORTH, N.J., May 14 ... SGP ), introduces COPPERTONE (R) , ... a new line of sunscreens enriched with antioxidants ... harmful free radicals created by UV exposure. ...
... convenience and broader access to an effective treatment ... frequent heartburn - Once-daily, prescription-strength Prevacid(R) 24HR is ... the treatment of frequent heartburn in the US ... heartburn for a full 24 hours BASEL, Switzerland, ...
... Significantly Impacted After Breaking a BoneSpecial Council of ... to Make Bone Health a Priority Before They ... Know My Bones Council today announced results ... that one-out-of-five women with postmenopausal osteoporosis (PMO) are ...
Other Medicine News:Health News:Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage 2Health News:Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage 3Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 2Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 3Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 4Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 5Health News:Cardiogenesis Reports First Quarter 2009 Results 2Health News:Cardiogenesis Reports First Quarter 2009 Results 3Health News:Cardiogenesis Reports First Quarter 2009 Results 4Health News:Cardiogenesis Reports First Quarter 2009 Results 5Health News:Cardiogenesis Reports First Quarter 2009 Results 6Health News:Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair 2Health News:Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair 3Health News:Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation 2Health News:Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation 3Health News:Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation 4Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 2Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 3Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 4Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 5Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 6Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 7Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 8Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 9
(Date:12/16/2009)... Inc., a Johnson & Johnson (NYSE: ... surgical care, and Acclarent, Inc., a privately held ... commercializing devices that address conditions affecting the ear, ... merger agreement whereby Ethicon will acquire Acclarent in ... of estimated cash on hand at time of ...
(Date:12/16/2009)... CHICAGO, Dec. 16 A ... to manage the clinical review of specialty pharmaceuticals ... number of drugs reviewed while reducing costs. ,, ... technology company with health plan clients representing over ... WellPoint, Inc. (NYSE: WLP ), adapted ...
(Date:12/16/2009)... Inc. (NYSE: HSP ), a leading global ... it will host a conference call to discuss its ... on Thursday, Feb. 4, 2010, at 8 a.m. Central ... full-year 2009 results earlier that morning, before the U.S. ... live webcast of the conference call will be available ...
Breaking Medicine Technology:Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4Senators Feinstein and Boxer Vote to Protect Americas Kids from Tobacco 48690 1Senators Feinstein and Boxer Vote to Protect Americas Kids from Tobacco 48690 2Travis McCoy Lead Vocalist 26 Songwriter of Alternative Hip Hop Band Gym Class Heroes Travels to South Africa Philippines and India as MTV Interna 48687 1Travis McCoy Lead Vocalist 26 Songwriter of Alternative Hip Hop Band Gym Class Heroes Travels to South Africa Philippines and India as MTV Interna 48687 2Travis McCoy Lead Vocalist 26 Songwriter of Alternative Hip Hop Band Gym Class Heroes Travels to South Africa Philippines and India as MTV Interna 48687 3Travis McCoy Lead Vocalist 26 Songwriter of Alternative Hip Hop Band Gym Class Heroes Travels to South Africa Philippines and India as MTV Interna 48687 4Travis McCoy Lead Vocalist 26 Songwriter of Alternative Hip Hop Band Gym Class Heroes Travels to South Africa Philippines and India as MTV Interna 48687 5Oclaro Launches Eye Safe High Power Laser Diodes at LASER 2009 48684 1Oclaro Launches Eye Safe High Power Laser Diodes at LASER 2009 48684 2Oclaro Launches Eye Safe High Power Laser Diodes at LASER 2009 48684 3
... Critique of Industry-Funded Immune Globulin Study Uncovers ... 2007 /PRNewswire-USNewswire/ -- An analysis,released today critically ... link between autism and Rh immune globulin,(RhIg) ... thimerosal. Besides extensive design flaws, the,analysis uncovered ...
... 27, 2007 - Columbia,Laboratories, Inc. (NASDAQ: CBRX) ... pharmacokinetic study of,vaginally-administered lidocaine, which the Company ... 42-subject study was designed to provide data ... vaginal lidocaine,formulation at three dose strengths over ...
Other Medicine Technology:Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 2Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 3Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 2Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 3
... Tecans MiniPrep series of robotic workstations ... The MiniPrep is the ideal automation ... automation of routine laboratory procedures, improving throughput, ... based Gemini for MiniPrep software allows you ...
... QFill2 is the ideal system for fast, accurate ... pressure driven, pinch valve controlled dispensing mechanism, ensures ... all of the components that come into contact ... clean, and autoclave. The unique compact design saves ...
... Automatic dispenser for low volumes. Dispenses ... 1536 -well format. Fast throughput of less ... productivity. The dispenser features an intuitive user ... be used to dispense liquids and suspensions, ...
... low volumes. Dispenses volumes down to 0.5ul ... throughput of less than 30 seconds per ... an intuitive user interface that provides one-button ... liquids and suspensions, beads, or cells, with ...
Medicine Products: